Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
Edward Gane,Eric Lawitz,David Pugatch,Georgios Papatheodoridis,Norbert Bräu,Norbert Bräu,Ashley Brown,Stanislas Pol,Vincent Leroy,Marcello Persico,Christophe Moreno,Massimo Colombo,Massimo Colombo,Eric M. Yoshida,David R. Nelson,Christine Collins,Yang Lei,Matthew P. Kosloski,Federico J. Mensa +18 more
TL;DR: Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection, and the primary end point was a sustained virology response 12 weeks after the end of treatment.
387
Historical epidemiology of hepatitis C virus (HCV) in selected countries
Philip Bruggmann,Thomas Berg,Anne Øvrehus,Christophe Moreno,C. E. Brandão Mello,Françoise Roudot-Thoraval,Rui Tato Marinho,Morris Sherman,Stephen D. Ryder,Jan Sperl,Ulus Salih Akarca,İsmail Balik,Florian Bihl,Marc Bilodeau,Antonio Javier Blasco,Maria Buti,Filipe Calinas,Jose Luis Calleja,Hugo Cheinquer,Peer Brehm Christensen,Mette Rye Clausen,Henrique Sérgio Moraes Coelho,Markus Cornberg,Matthew E. Cramp,Gregory J. Dore,Wahid Doss,Ann-Sofi Duberg,Manal H El-Sayed,Gül Ergör,Gamal Esmat,Chris Estes,Karolin Falconer,J. Félix,Maria Lucia Gomes Ferraz,Paulo R. Ferreira,S. Frankova,Javier García-Samaniego,Jan Gerstoft,José Giria,Fernando L. Gonçales,E. Gower,Michael Gschwantler,M Guimarães Pessôa,Christophe Hézode,Harald Hofer,Petr Husa,Ramazan Idilman,Martin Kåberg,Kelly Kaita,Achim Kautz,Sabahattin Kaymakoglu,Mel Krajden,Henrik Krarup,Wim Laleman,Daniel Lavanchy,Pablo Lázaro,Paul Marotta,S. Mauss,M. C. Mendes Correa,Beat Müllhaupt,Robert P. Myers,Francesco Negro,Vratislav Nemecek,Necati Örmeci,J Parkes,Kevork M. Peltekian,Kevork M. Peltekian,Alnoor Ramji,Homie Razavi,N. Reis,Stuart K. Roberts,William Rosenberg,Rui Sarmento-Castro,Christoph Sarrazin,David Semela,Gamal Shiha,William Sievert,Peter Stärkel,Rudolf E. Stauber,Alexander J. Thompson,Petr Urbánek,I. van Thiel,H. Van Vlierberghe,D. Vandijck,D. Vandijck,D. Vandijck,Wolfgang Vogel,Imam Waked,Heiner Wedemeyer,Nina Weis,Johannes Wiegand,Ayman Yosry,Amany Zekry,P. Van Damme,Soo Aleman,Soo Aleman,S. J. Hindman +96 more
TL;DR: In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use, and Diagnosis, treatment and transplant levels also differed considerably between countries.
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.
Richard Moreau,Joan Clària,Ferran Aguilar,François Fenaille,Juan José Lozano,Christophe Junot,Benoit Colsch,Paolo Caraceni,Jonel Trebicka,Marco Pavesi,Carlo Alessandria,Frederik Nevens,Faouzi Saliba,Tania M. Welzel,Agustín Albillos,Thierry Gustot,Javier Fernández,Christophe Moreno,Maurizio Baldassarre,Giacomo Zaccherini,Salvatore Piano,Sara Montagnese,Victor Vargas,Joan Genescà,Elsa Solà,William Bernal,Noémie Butin,Thaïs Hautbergue,Sophie Cholet,Florence Castelli,Christian Jansen,Christian J. Steib,Daniela Campion,R.P. Mookerjee,M.A. Rodríguez-Gandía,Germán Soriano,François Durand,Daniel Benten,Rafael Bañares,Rudolf E. Stauber,Henning Grønbæk,Minneke J. Coenraad,Pere Ginès,Alexander L. Gerbes,Rajiv Jalan,Mauro Bernardi,Vicente Arroyo,Paolo Angeli +47 more
TL;DR: Among patients with ACLF, the intensity of the fingerprint increased across ACLF grades, and was similar in patients with kidney failure and in those without, indicating that the fingerprint reflected not only decreased kidney excretion but also altered cell metabolism.
286
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
Homie Razavi,Sarah Robbins,Stefan Zeuzem,Francesco Negro,Maria Buti,Ann-Sofi Duberg,Françoise Roudot-Thoraval,Antonio Craxì,Michael Manns,Rui Tato Marinho,Béla Hunyady,Massimo Colombo,Soo Aleman,Krasimir Antonov,Perttu Arkkila,Kostas Athanasakis,Sarah Blach,M. Blachier,Antonio Javier Blasco,Filipe Calinas,Jose Luis Calleja,Peer Brehm Christensen,Matthew E. Cramp,E. A. Croes,Robert J. de Knegt,Victor de Ledinghen,Jean-Michel Delile,Chris Estes,Karolin Falconer,Martti Färkkilä,Robert Flisiak,Sona Frankova,Ivane Gamkrelidze,Javier García-Samaniego,Jordan Genov,Jan Gerstoft,Liana Gheorghe,Adrian Goldis,Ilias Gountas,Sergeja Gregorčič,Michael Gschwantler,Jessie Gunter,Waldemar Halota,Laura Harcouet,Christophe Hézode,Patrick Hoffmann,Gabor Horvath,Irena Hrstić,Peter Jarcuska,Deian Jelev,Agita Jeruma,Martin Kåberg,Jennifer Kieran,Loreta A. Kondili,Iskren Kotzev,Henrik Krarup,Pavol Kristian,Martin Lagging,Wim Laleman,Pablo Lázaro,Valentina Liakina,Boris Lukšić,Matti Maimets,Mihály Makara,Lyudmila Mateva,Mojca Matičič,Francesco Saverio Mennini,Rumiana Mitova,Christophe Moreno,Joël Mossong,Kimberly Murphy,Helen Nde,Vratislav Nemecek,Dijana Nonkovic,Suzanne Norris,Marian Oltman,Anne Øvrehus,George V. Papatheodoridis,Ken Pasini,Devin Razavi-Shearer,Kathryn Razavi-Shearer,Henk W. Reesink,Tatjana Reic,Baiba Rozentale,Stephen D. Ryder,Riina Salupere,Rui Sarmento-Castro,Christoph Sarrazin,Jonathan Schmelzer,Ivan Schréter,Carole Seguin-Devaux,Kaarlo Simojoki,Marietta Simonova,Peter J Smit,Kyriakos Souliotis,Danute Speiciene,Jan Sperl,Peter Stärkel,Daniel Struck,Vana Sypsa,Lelia Thornton,Ieva Tolmane,Krzysztof Tomasiewicz,Jonas Valantinas,Pierre Van Damme,David A. M. C. van de Vijver,Adriaan J. van der Meer,Daniela K van Santen,Hans Van Vlierberghe,Dominique Vandijck,Stefano Vella,Jerneja Videčnik-Zorman,Wolfgang Vogel,Nina Weis,Angelos Hatzakis +114 more
TL;DR: The EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets, and a united effort, grounded in sound epidemiological evidence, will also be necessary.
275
Differential liver sensitization to Toll‐like receptor pathways in mice with alcoholic fatty liver
Thierry Gustot,Arnaud Lemmers,Christophe Moreno,Nathalie Nagy,Eric Quertinmont,Charles Nicaise,Denis Franchimont,Hubert Louis,Jacques Devière,Olivier Le Moine +9 more
TL;DR: EtOH‐fed mice exhibited an oxidative stress dependent on upregulation of multiple TLRs in the liver and are sensitive to liver inflammation induced by multiple bacterial products recognized by TLRs.
242